Video
Author(s):
Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, shares his advice for oncologists treating patients with chronic lymphocytic leukemia.
Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, shares his advice for oncologists treating patients with chronic lymphocytic leukemia (CLL).
Chavez says to assess the patient as a whole—including genetics, poor prognosis, deletion—and remember that not all patients are the same. Young, fit patients can handle an intensive therapy regimen, while those with comorbidities need to be treated differently.
Additionally, Chavez says to not discount chemotherapy. Although new agents are causing excitement, chemotherapy still produces complete responses in patients with CLL.
T-DXd Plus Pembrolizumab Elicits Responses in IO-Naive HER2-Expressing or -Mutant NSCLC
Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC
Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
2 Commerce Drive
Cranbury, NJ 08512